Auregen Appoints Scott Lauder, Ph.D., As Chief Technology Officer
03/26/25, 11:39 AM
Location
cambridgeIndustry
therapeutics
biotechnology
health care
Position
chief technology officer
Auregen Biotherapeutics has announced the appointment of Scott Lauder, Ph.D., as Chief Technology Officer. Dr. Lauder brings deep expertise in innovative technologies and biologic modalities, and will play a crucial role in advancing the Phase 1/2 study for AUR-201, the company's first-in-class therapeutic ear replacement for people with microtia.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Auregen is a pioneering clinical-stage company developing precision approaches to restore functional anatomy with cartilage cell therapy. The company focuses on creating living tissue through GMP-compliant autologous cell expansion, with the aim of reducing the potential for rejection risk or donor supply dependency.